ReviewFrontiers in cardiovascular medicine2026
Global prevalence of hypertensive disorders of pregnancy: a scoping review and global perspective by country and region.
Review in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hypertensive disorders of pregnancy (HDP) are among the leading causes of maternal morbidity and mortality worldwide and an increasing global concern. This review aimed to estimate the global prevalence of HDP by country and World Health Organization (WHO) region using nationally representative, population-based studies. Methods: We searched PubMed and Embase for articles published between January 2004 and December 2023 and included population-based, observational studies with nationally or internationally representative samples reporting primary data on HDP prevalence. Study quality was assessed using a modified version of the Newcastle-Ottawa Scale. Results: A total of 143 studies from 31 countries across six WHO regions met the inclusion criteria. The African Region reported the highest prevalence of chronic hypertension (4.80%), gestational hypertension (17.50%), and composite HDP (22.20%), although nationally representative prevalence estimates for preeclampsia and eclampsia were not available for this region. In contrast, the Eastern Mediterranean Region reported the lowest rates of chronic hypertension (1.10%), gestational hypertension (1.70%), preeclampsia (1.45%), and HDP (5.10%). The European Region had intermediate rates of chronic hypertension (1.70%), gestational hypertension (2.90%), preeclampsia (2.50%), eclampsia (0.02%) and HDP (5.90%). The Americas Region and the Western Pacific Region had varying rates across the HDP spectrum: chronic hypertension (2.35%, 3.15%), gestational hypertension (5.10%, 1.98%), preeclampsia (5.35%, 2.45%), eclampsia (0.08%, 0.06%), and HDP (8.04%, 5.60%, respectively). High-income countries had more studies of higher methodological quality than low- and middle-income countries. Discussion: We observed considerable variability in HDP prevalence and study quality across countries and regions. This may stem from variations in screening methods, diagnostic criteria, and data availability, highlighting critical gaps in standardized protocols particularly in resource-limited settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.